down arrow

Trevi Therapeutics, Inc.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US89532M1018
USD
13.47
0.12 (0.9%)

Dec 04

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

13.3813.99

52 Week

2.3613.99
Valuation
Technical
Day's Volume

CASH

601.6 k

Shareholding (Mar 2025)

FII

5.13%

Held by 39 FIIs

DII

43.09%

Held by 21 DIIs

Promoter

40.26%

How big is Trevi Therapeutics, Inc.?

22-Jun-2025

As of Jun 18, Trevi Therapeutics, Inc. has a market capitalization of 729.17 million, categorizing it as a Micro Cap company. As of Jun 24, net sales for the latest four quarters are 0.00 million, with a net profit of -47.34 million.

As of Jun 18, Trevi Therapeutics, Inc. has a market capitalization of 729.17 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 24, the sum of net sales for the latest four quarters is 0.00 million, while the sum of net profit for the same period is -47.34 million.<BR><BR>As of Dec 24, the shareholder's funds amount to 99.64 million, and total assets are reported at 110.90 million.

Read More

What does Trevi Therapeutics, Inc. do?

22-Jun-2025

Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing nalbuphine ER for neurologically mediated conditions. As of March 2025, it has a market cap of $729.17 million and reported a net profit loss of $10 million.

Overview: <BR>Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing nalbuphine ER for treating neurologically mediated conditions within the Pharmaceuticals & Biotechnology industry.<BR><BR>Financial Snapshot: <BR>Most recent Net Profit: -10 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 729.17 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -1.04 <BR>Return on Equity: -47.61% <BR>Price to Book: 7.33<BR><BR>Contact Details: <BR>Address: 195 Church St Fl 14, NEW HAVEN CT: 06510-2009 <BR>Tel: 1 203 3042499 <BR>Fax: 1 203 3042434 <BR>Website: http://www.trevitherapeutics.com/

Read More

Who are in the management team of Trevi Therapeutics, Inc.?

22-Jun-2025

As of March 2022, the management team of Trevi Therapeutics, Inc. includes Dr. David Meeker (Independent Chairman), Ms. Jennifer Good (President, CEO, Co-Founder, Director), and Directors Mr. Dominick Colangelo, Mr. Edward Mathers, Dr. James Cassella, and Mr. Michael Heffernan.

As of March 2022, the management team of Trevi Therapeutics, Inc. includes Dr. David Meeker as the Independent Chairman of the Board, Ms. Jennifer Good as the President, Chief Executive Officer, Co-Founder, and Director, along with Mr. Dominick Colangelo, Mr. Edward Mathers, Dr. James Cassella, and Mr. Michael Heffernan, who serve as Directors.

Read More

Is Trevi Therapeutics, Inc. technically bullish or bearish?

20-Sep-2025

As of September 9, 2025, Trevi Therapeutics, Inc. has shifted to a bullish trend with strong technical indicators, outperforming the S&P 500 significantly with a year-to-date return of 107.28% compared to 12.22%.

As of 9 September 2025, the technical trend for Trevi Therapeutics, Inc. has changed from mildly bullish to bullish. The current stance is bullish with strong indicators supporting this view. The MACD is bullish on both the weekly and monthly time frames, and Bollinger Bands also indicate a bullish trend. Daily moving averages are bullish, while the KST shows bullish momentum on both weekly and monthly scales. Although the RSI is bearish on a monthly basis, the overall technical picture remains positive. <BR><BR>In terms of performance, Trevi Therapeutics has significantly outperformed the S&P 500 over multiple periods, with a year-to-date return of 107.28% compared to the S&P 500's 12.22%, and a one-year return of 150.44% versus 17.14%.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 926 Million ()

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-1.03

stock-summary
Return on Equity

-23.83%

stock-summary
Price to Book

4.66

Revenue and Profits:
Net Sales:
(Quarterly Results - Jun 2025)
Net Profit:
-12 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
88.39%
0%
88.39%
6 Months
126.39%
0%
126.39%
1 Year
384.53%
0%
384.53%
2 Years
1113.51%
0%
1113.51%
3 Years
532.39%
0%
532.39%
4 Years
1399.67%
0%
1399.67%
5 Years
347.51%
0%
347.51%

Trevi Therapeutics, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News

Is Trevi Therapeutics, Inc. technically bullish or bearish?

As of 9 September 2025, the technical trend for Trevi Therapeutics, Inc. has changed from mildly bullish to bullish. The current stance is bullish with strong indicators supporting this view. The MACD is bullish on both the weekly and monthly time frames, and Bollinger Bands also indicate a bullish trend. Daily moving averages are bullish, while the KST shows bullish momentum on both weekly and monthly scales. Although the RSI is bearish on a monthly basis, the overall technical picture remains positive. In terms of performance, Trevi Therapeutics has significantly outperformed the S&P 500 over multiple periods, with a year-to-date return of 107.28% compared to the S&P 500's 12.22%, and a one-year return of 150.44% versus 17.14%....

Read More
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
0
EBIT Growth (5y)
-20.93%
EBIT to Interest (avg)
-34.97
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.04
Sales to Capital Employed (avg)
0
Tax Ratio
0.07%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
100.00%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
8.46
EV to EBIT
-14.45
EV to EBITDA
-14.49
EV to Capital Employed
-209.47
EV to Sales
NA
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
-47.61%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Bullish
RSI
No Signal
Bearish
Bollinger Bands
Bullish
Mildly Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Bullish
Dow Theory
No Trend
Bullish
OBV
No Trend
Bullish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Strategic Entities

Domestic Funds

Held in 25 Schemes (11.52%)

Foreign Institutions

Held by 39 Foreign Institutions (5.13%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 0.81% vs -74.65% in Jun 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-13.70",
          "val2": "-13.30",
          "chgp": "-3.01%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-12.30",
          "val2": "-12.40",
          "chgp": "0.81%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -64.60% vs 0.34% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-51.40",
          "val2": "-33.80",
          "chgp": "-52.07%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.40",
          "chgp": "-100.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-47.90",
          "val2": "-29.10",
          "chgp": "-64.60%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoYstock-summary
Jun'25
Jun'24
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-13.70
-13.30
-3.01%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-12.30
-12.40
0.81%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is 0.81% vs -74.65% in Jun 2024

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-51.40
-33.80
-52.07%
Interest
0.00
0.40
-100.00%
Exceptional Items
0.00
0.00
Consolidate Net Profit
-47.90
-29.10
-64.60%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -64.60% vs 0.34% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About Trevi Therapeutics, Inc. stock-summary
stock-summary
Trevi Therapeutics, Inc.
Pharmaceuticals & Biotechnology
Trevi Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine ER to treat neurologically mediated conditions. The Company is engaged in developing nalbuphine ER for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and levodopa-induced dyskinesia (LID), in patients with Parkinson’s disease. The Company is conducting a Phase 2b/3 clinical trial of nalbuphine ER. The Company has also commenced a Phase 1b clinical trial in patients with chronic liver disease to evaluate the safety, pharmacokinetics and anti-pruritic effect of nalbuphine ER in this population. The Company’s nalbuphine ER development programs are Chronic Pruritus Programs, Prurigo Nodularis Program, Pruritus in Chronic Liver Disease Program and Uremic Pruritus Program.
Company Coordinates stock-summary
Company Details
195 Church St Fl 14 , NEW HAVEN CT : 06510-2009
stock-summary
Tel: 1 203 3042499
stock-summary
http://www.trevitherapeutics.com/
stock-summary
Registrar Details
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."